Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study.

Jiaxi ZhaoRong ChenMengqi LuoHongping GongKaixin LiQian Zhao

Published in: Diabetology & metabolic syndrome (2024)

The heightened expression of genetic variations in HMGCR inhibitor targets could potentially reduce the risk of IBD and CD, while genetic variation in the expression of NPC1L1 targets was positively associated with IBD.

Keyphrases

poor prognosis
ulcerative colitis
binding protein
genome wide
emergency department
fatty acid
drug induced
copy number